Navigation Links
Because of Its Ability to Generate Higher Total Sales in the United States and Europe, Lucentis Will Earn Clinical Gold Standard Status by 2011 for the Treatment of Diabetic Retinopathy
Date:6/26/2008

A Drug with Superior Efficacy to Avastin at Improving Visual Acuity When Used with Laser Photocoagulation Would Earn a 20 Percent Patient Share,

According to a New Report from Decision Resources

WALTHAM, Mass., June 26 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that Genentech/Novartis's Lucentis will become the Decision Resources' proprietary clinical gold standard by 2011 because of its ability to generate higher total sales in the United States and Europe due to its higher price. Although ophthalmologists perceive Lucentis as offering comparable efficacy to the current clinical gold standard, Avastin, Lucentis exhibits slightly greater affinity than Avastin to vascular endothelial growth factor (VEGF). If data continue to be positive for Avastin however, it will likely maintain a strong patient-share advantage over Lucentis and others because of its lower price.

The new report entitled Diabetic Retinopathy: Future Demand to Be Driven by Agents that Improve Visual Acuity also finds that a therapy that is more effective than Avastin at improving visual acuity when used in conjunction with laser photocoagulation therapy, would earn a 20 percent patient share in the treatment of diabetic retinopathy. Surveyed ophthalmologists indicate that an improvement -- not maintenance -- in visual acuity is fast becoming the target outcome of treatment for diabetic retinopathy including for patients with diabetic macular edema.

"Ophthalmologists we surveyed indicated that they would prescribe agents that fulfill either the Minimal Acceptable or Major Achievement profiles to 20 percent of their diabetic retinopathy patients," said Caroline Gates, B.Sc., analyst at Decision Resources. "Given the price set for each of the target product profiles and the forecasted size of the diabetic retinopathy patient population in 2011, a 20 percent patient share would result in sales of $42.7 million for an agent fitting the Minimal Acceptable drug profile and $320.3 million for an agent fitting the Major Achievement profile."

About the Report

Diabetic Retinopathy: Future Demand to Be Driven by Agents that Improve Visual Acuity is a DecisionBase 2008 report from Decision Resources. DecisionBase 2008 combines market forecasts with clinical and commercial end points to assess market share projections in 35 indications. These outputs are driven by quantitative and qualitative primary research. DecisionBase 2008 provides detailed market share, patient share, and price-per-day projections for emerging drugs in development. The market share projections are based on prescriber surveys that compare physicians' expectations of a potential target product profile with an emerging product profile of the leading drugs in development.

The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.

About Decision Resources

Decision Resources (http://www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

All company, brand, or product names contained in this document may be

trademarks or registered trademarks of their respective holders.


'/>"/>
SOURCE Decision Resources
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Emergency responders at high risk to miss work because of injuries
2. The American Red Cross Releases Book Devoted to Your Dogs Health - Because Your Dog is Counting on You
3. 13 percent of women stop taking breast cancer drug because of side effects, U-M study finds
4. GoAmerica(R) and AT&T to Demonstrate Fast, Effective 10-Digit Interoperability Between Video Relay Providers
5. Concuity Announces the Availability of PriceAdvisor
6. Launch of help2getbetter.com Provides Convenience and Portability to Household Medicines
7. Regence Pilot Shows Affordability of Electronic Medical Records
8. Baxter Releases Ninth Annual Sustainability Report
9. Human Factors International Sponsors Usability Professionals Association (UPA) 2008 International Conference
10. Ability to track stem cells in tumors could advance cancer treatments
11. Therap Services Announces Release 7.3 for the Developmental Disability Community
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ... 2017 , ... With millions of Americans and people worldwide ... all are aware of our options and are empowered with strength and information ... of its newest edition of "Vision and Hearing" in USA Today, that will ...
(Date:2/24/2017)... ... February 24, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at ... concerning this present generation. Yisrayl makes an astounding statement when he says that ... explains that the Bible details the current times so plainly that anyone should be ...
(Date:2/24/2017)... ... 2017 , ... Congratulations to Head Over Heels’ elite gymnast ... Ms. Esparza qualified into this prestigious status after winning the Vault, Floor, ... Nevada. Frida is one of approximately 25 gymnasts in the nation who earns ...
(Date:2/23/2017)... ... 2017 , ... The Lymphoma Research Foundation (LRF) – the ... the lymphoma community through a comprehensive series of education programs, outreach initiatives and ... Beach to host its Swirl: Miami Wine Tasting Event on March 28, 2017. ...
(Date:2/23/2017)... ... February 23, 2017 , ... Rosica Communications, a ... content marketing, social media management, corporate communications, SEO and cause marketing, is opening ... in nearby New Hampshire, Massachusetts and Canada, Rosica will focus on expanding its ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... 2017 Research and Markets has announced the addition ... report to their offering. ... The latest research Dry eye Drugs Price Analysis and Strategies - ... market. The research answers the following questions: ... clinical attributes? How are they positioned in the Global Dry eye market? ...
(Date:2/24/2017)... Juan Monteverde , founder and managing ... boutique securities firm headquartered at the Empire State Building ... that a class action lawsuit has been filed in the ... Inotek Pharmaceuticals Corporation (NASDAQ:  ITEK)("Inotek" or the "Company") on ... 2015 and December 30, 2016, inclusive (the "Class Period").  ...
(Date:2/24/2017)... ITL Limited, ( ASX : ITD ), une ... d,annoncer les excellents résultats semestriels clos le 31 décembre ... présentation complète « Résultats et mise à jour sur la ... Faits marquants ... $ ; en hausse de 104 %) Bénéfice ...
Breaking Medicine Technology: